OncoSec Medical to Present at Needham & Company's 14th Annual Healthcare Conference
SAN DIEGO-- OncoSec Medical Inc. (“OncoSec”) (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that CEO and President Punit Dhillon will present a corporate overview at Needham & Company’s 14th Annual Healthcare Conference on Tuesday, April 14, 2015 in New York City. The presentation is scheduled to begin at 8:40 AM ET at the Westin Grand Central Hotel.
Each year, Needham’s Healthcare Conference features presentations from approximately 100 companies in the biotechnology, specialty pharmaceutical, medical technology and diagnostic sectors. The conference focuses on connecting leading public and private life science companies and investors. One-on-one meetings with companies will be available for qualified institutional investors and venture capital firms. For more information, please visit: http://www.needhamco.com.
OncoSec invites investors and the general public to view and listen to the live webcast. At the time of the presentation, the webcast will be available via the following link: http://wsw.com/webcast/needham71/oncs. Please register at least 10 minutes prior to the start of the presentation to ensure timely access. After the presentation, an archived version of the webcast will be available for 90 days on OncoSec’s website: http://www.oncosec.com.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse intratumoral cancer immunotherapy. OncoSec’s core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response limiting the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase II development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Source: OncoSec Medical Inc.